Exploratory digital outcome measures of motor sign progression in Parkinson’s disease patients treated with prasinezumab

作者：Kirsten I. Taylor, Florian Lipsmeier, Marzia A. Scelsi, Ekaterina Volkova-Volkmar, Daria Rukina, Werner Popp, Stefan Lambrecht, Judith Anzures‐Cabrera, David Summers, Markus Abt, Annabelle Monnet, Timothy Kilchenmann, Jens Schjodt‐Eriksen, Laurent Essioux, Thomas Kustermann, Wagner Zago, Hanno Svoboda, Tania Nikolcheva, Ronald B. Postuma, Gennaro Pagano, Michael Lindemann, PASADENA Investigators, Claudia Altendorf, Chareyna Anandan, Giulia Andrews, Solène Ansquer, Raphaele Arrouasse, Sana Aslam, Jean-Philippe Azula, Jeanette Baker, Ernest Balaguer Martinez, Shadi Barbu, Kara Bardram, Danny Bega, H. Marco, Isabelle Bénatru, Eve Benchetrit, Felix Bernhard, Aris Raad Besharat, Sagari Betté, Amélie Bichon, Andrew Billnitzer, Sophie Blondeau, Thomas Boraud, Friederike Borngräber, James T. Boyd, Kathrin Brockmann, Matthew Brodsky, Ethan Brown, Christof Bruecke, Fabienne Calvas, Monica Canelo, Federico Carbone, Claire Carroll, Laura Casado‐Fernández, Catherine Casse-Parrot, Anna Castrioto, Hélène Catalá, Justine Chan, Samia Cheriet, Anthony Ciabarra, Joseph Claßen, Juliana Coleman, Robert R. Coleman, Yaroslau Compta, Jean-Christophe Corvol, Mariana Cosgaya, Nabila Dahodwala, Philippe Damier, Elodie David, Thomas L. Davis, Marissa Dean, Bérengère Debilly, Janell DeGiorgio, Andres Deik, Laure Delaby, Marie-Helene Delfini, Pascal Derkinderen, Philippe Derost, María de Toledo, Lisa M. Deuel, Ann Marie Diaz Hernandez, Cameron Dietiker, Karina Dimenshteyn, Julio Dotor, Franck Durif, Jens Ebentheuer, Karla Eggert, Sara Eichau, Claudia Eickoff, Aaron Ellenbogen, Philipp Ellmerer, Inés Esparragosa Vázquez, Alexandre Eusébio, Siobhán Ewert, John Fang, Danielle Feigenbaum, Frédérique Fluchère, Alexandra Foubert‐Samier, Marie Fournier, Anne Fradet, Valérie Fraix, Samuel Frank, Franka Fries, Monique Gailitzky, Anne Gaille Corbille, Marisol Gallardó Pérez, J.M. De La Morena, Carme Brun i Gasca, Thomas Gasser, Joyce Gibbons, Caroline Giordana, Alicia Gonzalez Martinez, Ira Goodman, A Gorospe, Marie Goubeaud, David Grabli, Mangone Graziella, Stéphan Grimaldi, Jeffrey M. Gross, Raquel Guimarães‐Costa, Andreas Hartmann, Christian J. Hartmann, Travis Hassell, Robert A. Hauser, Antonio Hernandez, Jorge Hernández‐Vara, Günter U. Höglinger, Christian Homedes, Andrea Horta, J.L. Houéto, Julius Huebl, Jennifer I. Hui, Stuart Isaacson, Joseph Jankovic, Annette Janzen, Jocelyne Jiao, María José Martí Domènech, X. Joseph, Srinath Kadimi, Pat Kaminski, Silja Kannenberg, Rebecca Kassubek, Maya Katz, Kevin J. Klos, Shannon Klos, Christopher Kobet, Jennifer Koebert, Patricia Krause, Andrea A. Kühn, Jaime Kulisevsky Bojarsky, Rajeev Kumar, M. Kunz, Lille Kurvits, Kimberly Kwei, Simon Laganiere, Brice Laurens, Johannes Levin, Oren Levy, Patricia L. Witt, Gurutz Linazasoro Cristóbal, Irene Litvan, Karlo J. Lizárraga, Katherine Longardner, Rocío López, Lydia López Manzanares, Sara Lucas Del Pozo, Maria Rosario Luquin Puido, Nijee Luthra, Kelly Lyons, Sylvia Maaß, Gerrit Machetanz, Yolanda Macías, David Maltête, Jorge U Máñez-Miró, Louise‐Laure Mariani, Juan Marín‐Lahoz, Kathrin Marini, Ana Marquès, Gloria Martí‐Andrés, Saul Martinez, Wassilios G. Meissner, Sara Meoni, Brit Mollenhauer, Dunia Mon Martinez, Johnson Moon, Elena Moro, Peter Morrison, Christoph Mühlberg, Manpreet Multani, Christine Murphy, Anthony P. Nicholas, Rajesh Pahwa, Antonio Palasis, Heidi Pape, Neepa Patel, Prity Patel, Marina Peball, Elizabeth Peckham, Terry Peery, Jesus Perez, Rafael L. Perez, Alisa Petit, Elmar H. Pinkhardt, Werner Poewe, Elsa Pomies, Cécile Preterre, Joseph Quinn, Olivier Rascol, Philippe Remy, Emily Reuther, Irene Hegeman Richard, Benjamin Röeben, Jost‐Julian Rumpf, David H. Russell, Hayet Salhi, Daniela Samaniego, Alexandra Samier‐Foubert, Álvaro Sánchez‐Ferro, Emmanuelle Schmitt, Alfons Schnitzler, Oliver Schorr, Julie Schwartzbard, Kerstin Schweyer, Klaus Seppi, Victoria Sergo, Holly A. Shill, Andrew Siderowf, Tanya Simuni, Umberto Spampinato, Ashok Sriram, Natividad Stover, Caroline Tanner, Arjun Tarakad, Carolyn Taylor, Claire Thalamus, Thomas B. Toothaker, Nadège Van Blercom, Nora Vanegas-Arrogave, Lydia Vela, Sylvian Vergnet, Tiphaine Vidal, Jonathan Vöglein, Ryan R. Walsh, Cheryl Waters, Mirko Wegschneider, Endy Weidinger, Caroline Weill, Gregor Wenzel, Tatiana Witjas, Isabel Wurster, Brenton A. Wright, Milan Zimmermann, Rafael Zuzuarregui, Prasinezumab Study Group, Atieh Bamdadian, Teresa Barata, Nicholas Barbet, Sara Belli, Frank Boess, Azad Bonni, Edilio Borroni, Anne Boulay, Markus Britschgi, Valérie Cosson, Christian Czech, Evan Davies, Dennis Deptula, Cheikh Diack, Rachelle S. Doody, Juergen Dukart, Giulia D’Urso, Sebastian Dziadek, Chris J. Edgar, Morgan Farell, Rebecca Finch, Paulo Fontoura, Waltraud Gruenbauer, Andrea Hahn, Štefan Holiga, Michael Honer, Shirin Jadidi, Thomas Kremer, Claire Landsdall, Cecile Paquet Luzy, Marianne Manchester, Maddalena Marchesi, Ferenc Martényi, Meret Martin‐Facklam, Katerina Mironova, Emma Moore, Markus Niggli, Susanne Ostrowitzki, Benedicte Passemard, Agnès Poirier, Anke Post, Megana Prasad, Nathalie Pross, Benedicte Ricci, Ellen Rose, Christoph Sarry, Christine M. Schubert, Jeff Sevigny, Kaycee M. Sink, Nima Shariati, Alexander Strasak, Hannah Staunton, Dylan Trundell, Daniel Umbricht, Lynne Verselis, Annamarie Vogt, Cornelia Weber, Silke Anna Theresa Weber, Stefano Zanigni · 发表于：npj Digital Medicine · 年份：2025 · DOI：10.1038/s41746-025-01572-8 · 被引用次数：13 · 研究领域：Parkinson's Disease Mechanisms and Treatments、Neurological disorders and treatments、Botulinum Toxin and Related Neurological Disorders

Digital health technology (DHT) tools for Parkinson's disease (PD) e.g., smartphones and wearables were used for remote and frequent measurement of motor signs in the phase 2 PASADENA study of the anti-alpha-synuclein monoclonal antibody prasinezumab. 316 early-stage PD participants were randomized to placebo, 1500 mg, or 4500 mg prasinezumab for 52 weeks; placebo participants were re-randomized to prasinezumab for the ensuing 52 weeks. Patients performed daily smartphone motor "active tests", and were passively monitored by smartphone/smartwatch throughout the day over 2 y. Change from baseline analyses censored data at dopaminergic treatment start. Bilateral speeded tapping variability and hand-turning, U-turn speed, passively monitored hand movement power, and summary Simple Sum scores progressed numerically less in prasinezumab-treated vs placebo at week 52. All findings except hand-turning persisted at week 104. DHT sensor-based outcome measures may contribute to quantifying disease progression in clinical research of early-stage, dopaminergic treatment-naïve PD. Clinical Trial Registry Name: ClinicalTrials.gov; Clinical Trial Registry ID: NCT03100149; registered 2017-03-29.